Source: Annual Congress 2008 - New treatments for asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Vincent, C. Banfield, T. Kakkar, S. Shakib, R. Scicchitano, T. Cheah, J. Gerson (Thousand Oaks, CA, United States Of America; Adelaide, Australia). Single-dose, first-in-human study of AMG 317: safety and pharmacokinetics in healthy and asthmatic adults. Eur Respir J 2008; 32: Suppl. 52, 3020

Member's Comments

No comment yet.

Related content which might interest you: Single-dose, first-in-human study of AMG 853: Pharmacokinetics, pharmacodynamics, and safety in healthy adults Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Multiple-dose study of AMG 317 in adults with asthma: pharmacokinetics and safety Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Multiple-dose study of AMG 853 in healthy adults: Safety and pharmacokinetics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 A phase 1, single-center, open-label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of treprostinil inhalation powder (TreT) in healthy normal volunteers Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 INTEGRIS-IPF: a 12-week, Phase 2a study evaluating the safety, tolerability and pharmacokinetics of PLN-74809 in participants with IPF Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Safety, pharmacokinetics and pharmacodynamics of BI 1323495 in healthy males Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020 Safety and tolerability of single doses of AZD5069 in healthy volunteers Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Safety, tolerability and pharmacokinetics of AZD9668, an oral neutrophil elastase inhibitor, in healthy subjects and patients with COPD Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004 Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301 Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Indacaterol, a novel β2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 332s Year: 2006 Dry powder inhaled ribavirin in healthy volunteers:  safety, tolerability, lung and systemic pharmacokinetics Source: International Congress 2017 – From microbiology to clinical work Year: 2017 Efficacy and safety of once-daily low-dose indacaterol/mometasone via Breezhaler® in symptomatic adult and adolescent patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 A double-blind, placebo-controlled, study to assess the pharmacokinetics, safety and tolerability of multiple ascending intravenous doses of CAT 354, a recombinant human anti-IL13 antibody, in subjects with moderate asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008